Gencurix Inc (229000) - Total Assets
Based on the latest financial reports, Gencurix Inc (229000) holds total assets worth ₩31.17 Billion KRW (≈ $21.12 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Gencurix Inc - Total Assets Trend (2016–2025)
This chart illustrates how Gencurix Inc's total assets have evolved over time, based on quarterly financial data. Also see market cap of Gencurix Inc for the company's overall valuation and market capitalisation.
Gencurix Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Gencurix Inc's total assets of ₩31.17 Billion consist of 53.2% current assets and 46.8% non-current assets. Review debt load of Gencurix Inc to assess the company's total debt and financial obligations.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 28.2% |
| Accounts Receivable | ₩3.75 Billion | 11.7% |
| Inventory | ₩529.49 Million | 1.7% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩1.02 Billion | 3.2% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Gencurix Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See 229000 live share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Gencurix Inc's current assets represent 53.2% of total assets in 2025, a decrease from 80.0% in 2016.
- Cash Position: Cash and equivalents constituted 28.2% of total assets in 2025, up from 0.0% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 1.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 11.7% of total assets.
Gencurix Inc Competitors by Total Assets
Key competitors of Gencurix Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
LONZA GROUP UNSP.ADR 1/10
F:LO3A
|
Germany | €17.91 Billion |
|
Healius Ltd
AU:HLS
|
Australia | AU$1.77 Billion |
|
Eurofins-Cerep SA
PA:ALECR
|
France | €88.84 Million |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$16.78 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$512.35 Million |
|
Cryosite Ltd
AU:CTE
|
Australia | AU$26.55 Million |
Gencurix Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.48 | 0.55 | 1.32 |
| Quick Ratio | 0.45 | 0.52 | 1.15 |
| Cash Ratio | 0.00 | 0.00 | 1.08 |
| Working Capital | ₩-9.44 Billion | ₩-6.27 Billion | ₩7.36 Billion |
Gencurix Inc - Advanced Valuation Insights
This section examines the relationship between Gencurix Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.61 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 6.9% |
| Total Assets | ₩32.11 Billion |
| Market Capitalization | $31.07 Million USD |
Valuation Analysis
Below Book Valuation: The market values Gencurix Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Gencurix Inc's assets grew by 6.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Gencurix Inc (2016–2025)
The table below shows the annual total assets of Gencurix Inc from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩32.11 Billion ≈ $21.76 Million |
+6.87% |
| 2024-12-31 | ₩30.04 Billion ≈ $20.36 Million |
-10.32% |
| 2023-12-31 | ₩33.50 Billion ≈ $22.70 Million |
-10.03% |
| 2022-12-31 | ₩37.24 Billion ≈ $25.24 Million |
-32.64% |
| 2021-12-31 | ₩55.29 Billion ≈ $37.47 Million |
-13.58% |
| 2020-12-31 | ₩63.98 Billion ≈ $43.36 Million |
+2579.67% |
| 2019-12-31 | ₩2.39 Billion ≈ $1.62 Million |
-76.46% |
| 2018-12-31 | ₩10.14 Billion ≈ $6.87 Million |
+37.79% |
| 2017-12-31 | ₩7.36 Billion ≈ $4.99 Million |
-20.27% |
| 2016-12-31 | ₩9.23 Billion ≈ $6.26 Million |
-- |
About Gencurix Inc
Gencurix Inc. provides diagnostic solutions in South Korea. Its products include GenesWell BCT, a multigene diagnostic test for breast cancer; Droplex, a genetic test based on digital PCR platform; eDX, an early diagnosis for cancer with liquid biopsy; GenePro SARS-CoV-2 Test kit; GenoCTC, a circulating tumor cell isolator; and GenePro LAMP Cycler, a portable device for infectious disease detecti… Read more